Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
- PMID: 31862245
- DOI: 10.1016/S2214-109X(19)30488-7
Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis
Abstract
Background: Infectious pathogens are strong and modifiable causes of cancer. The aim of this study was to improve estimates of the global and regional burden of infection-attributable cancers to inform research priorities and facilitate prevention efforts.
Methods: We used the GLOBOCAN 2018 database of cancer incidence and mortality rates and estimated the attributable fractions and global incidence for specific anatomical cancer sites, subsites, or histological subtypes known to be associated with ten infectious pathogens classified as human carcinogens. We calculated absolute numbers and age-standardised incidence rates (ASIR) of infection-attributable cancers at the country level. Estimates were stratified for sex, age group, and country, and were aggregated according to geographical regions and World Bank income groups.
Findings: We found that, for 2018, an estimated 2·2 million infection-attributable cancer cases were diagnosed worldwide, corresponding to an infection-attributable ASIR of 25·0 cases per 100 000 person-years. Primary causes were Helicobacter pylori (810 000 cases, ASIR 8·7 cases per 100 000 person-years), human papillomavirus (690 000, 8·0), hepatitis B virus (360 000, 4·1) and hepatitis C virus (160 000, 1·7). Infection-attributable ASIR was highest in eastern Asia (37·9 cases per 100 000 person-years) and sub-Saharan Africa (33·1), and lowest in northern Europe (13·6) and western Asia (13·8). China accounted for a third of worldwide cancer cases attributable to infection, driven by high ASIR of H pylori (15·6) and hepatitis B virus (11·7) infection. The cancer burden attributed to human papillomavirus showed the clearest relationship with country income level (from ASIR of 6·9 cases per 100 000 person-years in high-income countries to 16·1 in low-income countries).
Interpretation: Infection-attributable cancer incidence, in addition to the absolute number of cases, allows for refined geographic analyses and identification of populations with a high infection-associated cancer burden. When cancer prevention is largely considered in a non-communicable disease context, there is a crucial need for resources directed towards cancer prevention programmes that target infection, particularly in high-risk populations. Such interventions can markedly reduce the increasing cancer burden and associated mortality.
Funding: International Agency for Research on Cancer.
© 2020 International Agency for Research on Cancer; licensee Elsevier. This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is properly cited. This article shall not be used or reproduced in association with the promotion of commercial products, services or any entity. There should be no suggestion that IARC endorses any specific organisation, products or services. The use of the IARC logo is not permitted. This notice should be preserved along with the article's original URL.
Comment in
-
Global burden of cancer attributable to infections: the critical role of implementation science.Lancet Glob Health. 2020 Feb;8(2):e153-e154. doi: 10.1016/S2214-109X(20)30001-2. Lancet Glob Health. 2020. PMID: 31981543 No abstract available.
Similar articles
-
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet Respir Med. 2021 Sep;9(9):1030-1049. doi: 10.1016/S2213-2600(21)00164-8. Epub 2021 Aug 16. Lancet Respir Med. 2021. PMID: 34411511 Free PMC article.
-
Burden of non-communicable diseases from infectious causes in 2017: a modelling study.Lancet Glob Health. 2020 Dec;8(12):e1489-e1498. doi: 10.1016/S2214-109X(20)30358-2. Epub 2020 Oct 21. Lancet Glob Health. 2020. PMID: 33098769 Free PMC article.
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
Global burden of cancers attributable to infections in 2012: a synthetic analysis.Lancet Glob Health. 2016 Sep;4(9):e609-16. doi: 10.1016/S2214-109X(16)30143-7. Epub 2016 Jul 25. Lancet Glob Health. 2016. PMID: 27470177
-
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis.Lancet Oncol. 2012 Jun;13(6):607-15. doi: 10.1016/S1470-2045(12)70137-7. Epub 2012 May 9. Lancet Oncol. 2012. PMID: 22575588 Review.
Cited by
-
Addressing the burden of cervical cancer for Indigenous women in Latin America and the Caribbean: a call for action.Front Public Health. 2024 May 14;12:1376748. doi: 10.3389/fpubh.2024.1376748. eCollection 2024. Front Public Health. 2024. PMID: 38807996 Free PMC article. Review.
-
Role of Exosomes in Cancer and Aptamer-Modified Exosomes as a Promising Platform for Cancer Targeted Therapy.Biol Proced Online. 2024 May 27;26(1):15. doi: 10.1186/s12575-024-00245-2. Biol Proced Online. 2024. PMID: 38802766 Free PMC article. Review.
-
Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates.Sci Rep. 2024 May 27;14(1):12066. doi: 10.1038/s41598-024-62200-1. Sci Rep. 2024. PMID: 38802465 Free PMC article.
-
Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.Vaccines (Basel). 2024 May 13;12(5):533. doi: 10.3390/vaccines12050533. Vaccines (Basel). 2024. PMID: 38793784 Free PMC article. Review.
-
Effect of an HPV Vaccination Multi-Level, Multi-Component Program on HPV Vaccination Initiation and Completion in a Pediatric Clinic Network.Vaccines (Basel). 2024 May 8;12(5):510. doi: 10.3390/vaccines12050510. Vaccines (Basel). 2024. PMID: 38793761 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical